Wayne Winegarden
Blog
Imposing Price Controls on U.S. Drugs Won’t Level the Playing Field
The cost of capital for developing a new drug is $2.9 billion, including post approval research and development costs. Meanwhile, the process to develop a drug takes 10 years and only 12 percent of drugs make it to market. These costs do not change simply because governments impose price controls ...
Commentary
Growing LNG Exports Demonstrate The Benefits Of Deregulation
Less than three years ago, Germany was capping energy prices and considering rationing fuel as Europe scrambled to replace cheap Russian oil and natural gas. Today the German market is well supplied and, as of March 10, 2025, no shortages are anticipated. Transformative investments in U.S. based liquefied natural gas ...
Biosimilars
Fixing The Regulatory Flaws Biosimilars Face Will Help Patients
About a month ago, the Centers for Medicare & Medicaid Services announced the next 15 drugs that will be subject to the maximum fair price (MFP) negotiation process. These negotiations are essentially a means to impose price controls on selected medicines. If the Trump Administration truly wants to help patients, ...
Blog
Spending Watch
Backfilling Lost Federal Education Funding Will Cost California Dearly
Backfilling Lost Federal Education Funding Will Cost California Dearly Wayne Winegarden February 2025 The erratic actions of the Trump Administration are undoubtedly making it more difficult for states to budget for the upcoming 2026 fiscal year. The knee-jerk reaction from many California politicians is to call for more taxes on ...
Business & Economics
Tariffs Harm American Consumers, Manufacturers and the Economy, Warns New Study
SACRAMENTO – Recently enacted and proposed tariffs will have devastating consequences for American families, businesses, and the overall economy, according to a new study by the Pacific Research Institute. The report, authored by economist Dr. Wayne Winegarden, finds that tariffs will lead to higher consumer prices, increased manufacturing costs, and ...
Commentary
President Trump Unleashes a New Energy Future Benefiting Americans
On January 20, the U.S. Department of Energy ended the Biden Administration’s misguided pause on processing new Liquefied Natural Gas (LNG) export applications. This is great news. The Biden policy never made sense and unwisely inhibited efforts to export more LNG, particularly to our EU trading partners. Read the entire ...
Blog
Read about a last minute Biden administration plan the Trump administration should undo
CMS’ Drug Price Controls Have Expanded to the Next 15 Medicare Part D Drugs
For every complex problem there is an answer that is clear, simple, and wrong. H.L. Mencken Back in 2022, the Biden Administration reasoned that drug costs are too high and devised a clear and simple answer: incorporate a Maximum Fair Price (MFP) provision into the Inflation Reduction Act of 2022 ...
Biosimilars
The Biosimilar Promise
Reforms Can Improve Competition and Generate More Savings
Reforms Can Improve Competition and Generate More Savings By Wayne Winegarden | January 7, 2025 READ PDF Executive Summary Reforms that will strengthen the biosimilar market and expand savings opportunities include: Reforming (ideally repealing) the Inflation Reduction Act’s price control measures. Improving the incentives underlying the current buy-and-bill system to ...
Blog
Grants Pass and Prop 36 Will Help Policymakers Control California’s Homeless Crisis
Between 2007 and 2014, homelessness declined faster in California than the rest of the country – an 18 percent total decline in California compared to a 9 percent total decline in the rest of the country. And then something happened in 2014. While the number of homeless in California began ...
Biosimilars
The Biosimilar Promise
Despite Achievements, Barriers That Discourage Biosimilar Use Remain
Despite Achievements, Barriers That Discourage Biosimilar Use Remain By Wayne Winegarden | December 2, 2024 READ PDF Executive Summary The Inflation Reduction Act’s price controls discourage biosimilar development. Payment system inefficiencies, such as the buy-and-bill payment system and rebate walls, disincentivize the use of lower cost biosimilars. Despite the savings ...
Imposing Price Controls on U.S. Drugs Won’t Level the Playing Field
The cost of capital for developing a new drug is $2.9 billion, including post approval research and development costs. Meanwhile, the process to develop a drug takes 10 years and only 12 percent of drugs make it to market. These costs do not change simply because governments impose price controls ...
Growing LNG Exports Demonstrate The Benefits Of Deregulation
Less than three years ago, Germany was capping energy prices and considering rationing fuel as Europe scrambled to replace cheap Russian oil and natural gas. Today the German market is well supplied and, as of March 10, 2025, no shortages are anticipated. Transformative investments in U.S. based liquefied natural gas ...
Fixing The Regulatory Flaws Biosimilars Face Will Help Patients
About a month ago, the Centers for Medicare & Medicaid Services announced the next 15 drugs that will be subject to the maximum fair price (MFP) negotiation process. These negotiations are essentially a means to impose price controls on selected medicines. If the Trump Administration truly wants to help patients, ...
Spending Watch
Backfilling Lost Federal Education Funding Will Cost California Dearly
Backfilling Lost Federal Education Funding Will Cost California Dearly Wayne Winegarden February 2025 The erratic actions of the Trump Administration are undoubtedly making it more difficult for states to budget for the upcoming 2026 fiscal year. The knee-jerk reaction from many California politicians is to call for more taxes on ...
Tariffs Harm American Consumers, Manufacturers and the Economy, Warns New Study
SACRAMENTO – Recently enacted and proposed tariffs will have devastating consequences for American families, businesses, and the overall economy, according to a new study by the Pacific Research Institute. The report, authored by economist Dr. Wayne Winegarden, finds that tariffs will lead to higher consumer prices, increased manufacturing costs, and ...
President Trump Unleashes a New Energy Future Benefiting Americans
On January 20, the U.S. Department of Energy ended the Biden Administration’s misguided pause on processing new Liquefied Natural Gas (LNG) export applications. This is great news. The Biden policy never made sense and unwisely inhibited efforts to export more LNG, particularly to our EU trading partners. Read the entire ...
Read about a last minute Biden administration plan the Trump administration should undo
CMS’ Drug Price Controls Have Expanded to the Next 15 Medicare Part D Drugs
For every complex problem there is an answer that is clear, simple, and wrong. H.L. Mencken Back in 2022, the Biden Administration reasoned that drug costs are too high and devised a clear and simple answer: incorporate a Maximum Fair Price (MFP) provision into the Inflation Reduction Act of 2022 ...
The Biosimilar Promise
Reforms Can Improve Competition and Generate More Savings
Reforms Can Improve Competition and Generate More Savings By Wayne Winegarden | January 7, 2025 READ PDF Executive Summary Reforms that will strengthen the biosimilar market and expand savings opportunities include: Reforming (ideally repealing) the Inflation Reduction Act’s price control measures. Improving the incentives underlying the current buy-and-bill system to ...
Grants Pass and Prop 36 Will Help Policymakers Control California’s Homeless Crisis
Between 2007 and 2014, homelessness declined faster in California than the rest of the country – an 18 percent total decline in California compared to a 9 percent total decline in the rest of the country. And then something happened in 2014. While the number of homeless in California began ...
The Biosimilar Promise
Despite Achievements, Barriers That Discourage Biosimilar Use Remain
Despite Achievements, Barriers That Discourage Biosimilar Use Remain By Wayne Winegarden | December 2, 2024 READ PDF Executive Summary The Inflation Reduction Act’s price controls discourage biosimilar development. Payment system inefficiencies, such as the buy-and-bill payment system and rebate walls, disincentivize the use of lower cost biosimilars. Despite the savings ...
